(Date:12/11/2009)... ASA (OSE: ALGETA), the,cancer therapeutics company, announces ... the Tulane Cancer Center, New Orleans, has ... study of Alpharadin in men with,castration-resistant (also ... metastasized to the skeleton. , ... Prostate CAncer) study is a,double-blind, randomized, controlled ...
(Date:12/11/2009)... Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, ... announced the appointment of Dr. Alan Warrander to ... and Business Development. ,, "Dr. Warrander will be ... strategy for REOLYSIN(R)," said Dr. Brad Thompson, President ... on the design of a Phase 3 trial ...
(Date:12/10/2009)... -- Microban International, Ltd., the global leader ... with Sharp Imaging and Information Company of ... incorporate it,s third generation silver-based antimicrobial technology ... the calculator keys during manufacture, Microban ® ... damaging bacteria on the keys. ,, ...
(Date:12/10/2009)... Dec. 10 With the economy and markets ... Street,s largest, fastest-growing small cap equity research provider, will ... investment opportunities within the micro cap market at the ... January 11, 2010 at the Grand Hyatt Hotel in ... are overlooked and undervalued by much of Wall Street, ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2